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Cannabis use is highly prevalent in patients with schizophrenia and worsens the course of the disorder. To
understand how exposure to cannabis changes schizophreniarelated oscillatory disruptions, we investigated the impact of administering cannabis vapor containing either
Δ9-tetrahydrocannabinol (THC) or balanced THC/
cannabidiol (CBD) on oscillatory activity in the neonatal
ventral hippocampal lesion (NVHL) rat model of schizophrenia. Male Sprague Dawley rats underwent lesion or
sham surgeries on postnatal day 7. In adulthood, electrodes
were implanted targeting the cingulate cortex (Cg), the
prelimbic cortex (PrLC), the hippocampus (HIP), and the
nucleus accumbens (NAc). Local field potential recordings
were obtained after rats were administered either the
“THC-only” cannabis vapor (8–18% THC/0% CBD) or the
“Balanced THC:CBD” cannabis vapor (4–11% THC/8.5–
15.5% CBD) in a cross-over design with a 2-week wash-out
period between exposures. Compared to controls, NVHL
rats had reduced baseline gamma power in the Cg, HIP,
and NAc, and reduced HIP-Cg high-gamma coherence.
THC-only vapor exposure broadly suppressed oscillatory
power and coherence, even beyond the baseline reductions
observed in NHVL rats. Balanced THC:CBD vapor, however, did not suppress oscillatory power and coherence, and
in some instances enhanced power. For NVHL rats, THConly vapor normalized the baseline HIP-Cg high-gamma
coherence deficits. NHVL rats demonstrated a 20 ms delay
in HIP theta to high-gamma phase coupling, which was not
apparent in the PrLC and NAc after both exposures. In
conclusion, cannabis vapor exposure has varying impacts
on oscillatory activity in NVHL rats, and the relative composition of naturally occurring cannabinoids may contribute to this variability.

Key
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Introduction
Lifetime rates of cannabis use and cannabis use disorder
in patients with schizophrenia are reported to be as high
as 80% and 50%, respectively.1 Concerningly, this use is
associated with worsened clinical outcomes for patients
through symptom exacerbation, treatment noncompliance, as well as increased rates of hospitalization and relapse1–3; however, patients also report positive outcomes
including enhanced socializing and reduced anxiety.4–6
The varying outcomes of cannabis use for patients with
schizophrenia may reflect different methods of use, or
the phytochemical diversity of the cannabis plant.7–9
With over 113 constituents, or “cannabinoids”, in the
cannabis plant, their relative composition dictates the
effects produced.10 Scientific investigation has mainly
focused on two cannabinoids due to their abundance
in the plant and relevance for biomedical research:
Δ9-tetrahydrocannabinol (THC), the main psychoactive
constituent that binds with endogenous cannabinoid type
1 receptors (CB1Rs) to produce the rewarding and psychotomimetic effects.10–13 Cannabidiol (CBD), which has
some psychoactive effects, does not produce the psychotomimetic effects seen with THC.14,15 CBD also acts as a
negative allosteric modulator of CB1Rs and may also act
as a partial agonist of both the cannabinoid type 2 and
dopamine type 2 receptors, with growing evidence that
it may, at least partially, interact agonistically with serotonin 1A receptors.16–21 The independent effects of these
cannabinoids differ from the combined effects, and these
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stimulation of the ventral tegmental area (VTA), an effect that is absent in rats lesioned in adulthood.36
Similar to the observations from rodents used to
model schizophrenia, we previously published data
demonstrating acute THC (10 mg/kg) vapor exposure in
experimentally naïve rats suppresses LFP gamma (30–
100 Hz) power and coherence in the dorsal striatum, the
PFC, and the orbitofrontal cortex.37 LFP recordings from
the HIP and entorhinal cortex of experimentally naïve
rats administered CB1R agonist CP-55,940 (0.3 mg/kg,
IP) also demonstrate reduced evoked theta (4–7 Hz)
and gamma (30–80 Hz) power, which was corroborated
in healthy humans administered THC (0.035 mg/kg,
IV) using whole-brain electroencephalography (EEG);
human subjects were also administered CBD (5 mg,
IV), either alone or combined with THC, and while the
combined treatment produced similar effects to THC
alone, CBD alone had no effects on brain activity.38
Considering the clinical and preclinical evidence of altered neural circuit activity associated with cannabinoid
exposure and the symptoms of schizophrenia, as well as
reports of the oppositional effects between THC and CBD
on neural circuit activity, we herein aimed to (1) assess
baseline differences in corticolimbic LFPs between NVHL
rats and sham-surgery (sham) controls, and (2) assess LFP
changes in NVHL and sham rats resulting from cannabis
vapor exposure, with and without CBD. We hypothesized
that NVHL rats demonstrate reduced corticolimbic oscillatory activity, reflecting observations from preclinical and clinical studies of schizophrenia. We further
hypothesized that exposure to cannabis vapor without
CBD will worsen oscillatory dysfunctions in NVHL rats
compared to sham rats, while exposure to cannabis vapor
with CBD may ameliorate some of the lesion-induced
deficits. We targeted the prelimbic cortex (PrLC), the cingulate cortex (Cg), the HIP, and the nucleus accumbens
(NAc) due to their involvement in mesocorticolimbic
signaling pathways, drug-seeking behavior, and the pathophysiology of schizophrenia. To maintain translational
relevance, we administered cannabinoids as they naturally
exist in the cannabis plant, by exposing NVHL and sham
rats to vaporized cannabis flower (i.e., dried plant matter)
using a consumer-grade cannabis vaporizer.
Methods
Animals
Ten male Sprague Dawley rat pups with lactating dam
were purchased from Charles River (Senneville, Quebec,
Canada). Rats were housed in a colony room maintained
on a 12-hour light:dark cycle with ad libitum access to
food and water. Prior to the start of experiments, rats
were habituated to the experimental environment for
2 min daily and for a total of 5 days. All treatments were
performed during the light phase of the 12-hour reverse light:dark cycle. All procedures complied with the
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differential effects further vary by administration route.22–
24
Interestingly, CBD often mitigates the psychoactive
effects of THC and may have antipsychotic properties.25–28
Consistent with this, Wall et al.7 recently used magnetic resonance imaging (MRI) to measure functional
connectivity changes in the default mode network
(DMN, measured as increased functional connectivity
of the posterior cingulate cortex), executive control
network (ECN, negatively correlated with DMN activity and measured as reduced connectivity in the posterior cingulate cortex), and salience network (SAL,
measured as increased connectivity within the anterior
insula), after healthy subjects were administered either
vaporized placebo cannabis, cannabis with THC (8 mg)
and CBD (10 mg), or cannabis without CBD (THC:
8 mg). Cannabis vapor reduced DMN connectivity relative to placebo, while not significantly affecting ECN
connectivity. Only vapor without CBD impacted SAL
connectivity, reducing it relative to vapor with CBD.
Reduced DMN activity was correlated with the selfreported psychoactive effects of THC whereas exposure to vapor with CBD had a restorative effect.7
Altered neural circuit activity is also apparent in
mesocorticolimbic brain regions of rodents used to
model schizophrenia and in experimentally naïve rats
after cannabinoid exposure.29 Local field potential (LFP)
recordings from Wistar rats selectively bred as a model of
schizophrenia to exhibit maximal disruptions after postweaning social isolation and subchronic ketamine administration (20 mg/kg, intraperitoneal [IP]), demonstrate
enhanced upper theta (4–8 Hz) and beta (13–30 Hz) spectral power in the parietal cortex, as well as reduced delta
(0.6–4 Hz) and high-gamma (71–100 Hz) power.30 In
contrast, LFP recordings from rats used to model schizophrenia that underwent neonatal ventral hippocampal
lesions (NVHL rats) demonstrate reduced evoked delta,
theta, and beta power31 compared to controls, as well as
reduced theta (5–15 Hz) and beta (20–30 Hz) coherence
in the hippocampus (HIP), with intact coherence in the
medial prefrontal cortex (PFC).32 Additionally, NVHL
rats do not exhibit stereotypical increases in phaselocking of auditory evoked potentials to increasing
stimulus frequencies, measured in the temporal cortex.33
Importantly, the dysfunctions modeled in NVHL rats are
not singularly due to the lesion but are instead the result of the neurodevelopmental insult produced by the
lesion. Compared to controls, NVHL rats demonstrate
impaired working memory measured using a T-maze decision making task, whereas adult rats that underwent
ventral hippocampal lesions demonstrate intact working
memory.34 NVHL rats also demonstrate enhanced neuronal activity in striatal and cortical regions, measured as
enhanced ΔFosB expression compared to controls, while
this difference was absent in rats lesioned in early adulthood.35 NVHL rats also demonstrate enhanced firing of
medial PFC pyramidal neurons in response to electrical

Cannabis Constituents And Schizophrenia-like Oscillations

guidelines described in the Guide to the Care and Use
of Experimental Animals (Canadian Council on Animal
Care, 1993) and set by the Animal Care Committee at the
University of Guelph.

The NVHL rat was produced as previously described.39,40
Considered a valuable heuristic model of schizophrenia and co-occurring substance use,41 including in
the context of cannabis use and schizophrenia,42,43 this
neurodevelopmental model involves bilaterally lesioning
the ventral hippocampi of rat pups using ibotenic acid.
This model has (a) face validity, in that it produces behavioral and neural circuit changes reflecting those observed
in schizophrenia, on a similar neurodevelopmental
timeline; (b) construct validity, as it is based on the
neurodevelopmental hypothesis of schizophrenia and
involves an early neurodevelopmental insult to the ventral hippocampus, consistent with anterior hippocampal
dysfunctions in patients; and (c) predictive validity, in
that NVHL rats respond to antipsychotics in a manner
reflective of outcomes observed in humans with schizophrenia.39,44 On postnatal day 7 (PND7), rat pups were
anesthetized via hypothermia, injected with either 0.3 μL
of ibotenic acid (Sigma–Aldrich, Oakville, Ontario,
Canada; for NVHL rats) or artificial cerebrospinal fluid
(aCSF, for sham rats) into the ventral hippocampus (anterior–posterior [AP]: −3 mm; medial-lateral [ML]: ±
3.5 mm; dorsal-ventral [DV]: −5 mm) at a rate of 0.1 μL/
min over 3 min, followed by a two-minute wait period.
Animals were housed with dam in polyethylene cages
(Allentown, Allentown, NJ, USA) until weaning, and
pair-housed until the electrode implantation surgeries.
Electrode Implantation Surgeries
Electrode implantation was performed as previously described.45 Custom-built, 10-channel electrode
microarrays were constructed using Delrin templates46,47
and polyimide-insulated stainless-steel wires (791600,
0.008”, A-M Systems, Carlsborg, Washington, USA)
attached to a single-row connector. All arrays had
an electrode impedance of less than 2 MΩ. Rats were
anesthetized with isoflurane (5%), affixed in a stereotaxic
apparatus (Kopf Instruments, Tujunga, CA), and
electrode arrays were implanted bilaterally into the
prelimbic cortex (PrLC; AP: +3.24 mm, ML: ±0.6 mm,
DV: −3.8 mm), the cingulate cortex (Cg; AP: +1.9 mm,
ML: ±0.5 mm, DV: −2.8 mm), the CA1 region of the
hippocampus (HIP; AP: −3.5 mm, ML: ±2.5 mm,
DV: −2.6 mm), and the nucleus accumbens (NAc; AP:
+1.9 mm, ML: ±1.2 mm, DV: −6.6 mm). Animals
recovered in their home cage for a minimum of 7 days
prior to experimentation.

Cannabis flower vapor administration was performed
using our customized OpenVape apparatus with a Utillian
420 (Utillian, Toronto, Ontario, Canada) dried herb vaporizer.48–50 A randomized, within-study crossover design
was used as performed in human subjects and in our previous study with experimentally naïve rats22,37 (figure 1A).
Rats were randomly assigned to two groups (N = 5/group)
for exposure to either cannabis vapor with 8%–18%
THC and 0% CBD (Summer Fling, Aurora, Edmonton,
Alberta, Canada; “THC-only” exposure group) or
4%–11% THC and 8.5%–15.5% CBD (Balance, Solei,
Leamington, Ontario, Canada; “Balanced THC:CBD”
exposure group). Ground cannabis flower was vaporized
at 200°C and channeled into a mouse cage (40 × 20 ×
20 cm) holding two rats at a time. For each minute of
the first 5 min the rats were in the chamber, 10 puffs were
delivered for 2 s total with a four-second interpuff interval. Rats remained in the chamber for another 5 min
such that the duration of exposure was 10 min total. The
chamber was vented with clean air by removal of the cage
lid. All vapor administration procedures occurred under
a fume hood to remove any side-stream vapor.
Electrophysiology
LFP recordings (W2100-system, Multichannel Systems,
Kusterdingen, Germany) were performed in awake, freely
moving rats exploring clear plexiglass boxes (45 cm × 45 cm
× 45 cm). Recordings were taken from five animals with
two electrodes/animal/region resulted in a final sample size
of 10. Baseline recordings were collected 24 h before the
first vapor exposure, and immediately before each cannabis
vapor exposure, for 30 min at a rate of 1000 samples/s.
MATLAB (MathWorks, Natick, MA, USA) routines using
the Chronux software package were used to analyze the
spectral power of each brain region, as well as coherence
and theta–gamma cross-correlation between brain regions.
Five-minute epochs were used, with epochs segmented,
detrended, denoised, and low-pass filtered to remove
frequencies greater than 100 Hz. Continuous multitaper
spectral power for data normalized to total spectral power
and coherence (tapers = [5 9]) was calculated for delta (1–4
Hz), theta (>4–12 Hz), beta (>12–30 Hz), low gamma
(>30–60 Hz), and high gamma (>60–100 Hz).
Histology
After experimentation, rats were euthanized by carbon dioxide + isoflurane before their brains were extracted and
flash frozen. Brains were subsequently sectioned (at 40 μm)
using a cryostat, mounted on slides, and stained with
thionin. The Cg, PrLC, HIP, and NAc were examined microscopically to confirm electrode placement and bilateral
lesioning. Rats with unilateral or extrahippocampal lesions
or misplace electrodes would be removed from the analyses.
Page 3 of 14
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Data Analysis
Analysis was performed on one-minute time bins with
data curves presented as normalized data with jack-knife
estimates of standard error of the mean (SEM). Data
were log-transformed to better exhibit group differences.
Prior to all analyses, normality was assessed using the
Page 4 of 14

Shapiro–Wilk test. Sham or NVHL group comparisons
were performed using a repeated measures ANOVA with
treatment as the within-subjects factor, followed by paired
t-tests. A Student’s t-test was used to compare NVHL
exposure groups to baseline sham data. Computations
were performed using IBM SPSS 24 software and are
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Fig. 1. Experimental design, lesion and electrode verification, and representative local field potential tracing. A) Cross-over design with
a two-week wash-out period between exposures B) Electrode placements (top) and lesion (bottom) showing electrode termini (blue) in
the PrLC (left), Cg + NAc (middle), and HIP (right), as well as lesion extent in all NVHL rats (purple represents size of smallest and
pink represents size of largest lesions), compared to sham controls. C) Representative tracings from the Cg showing changes in theta and
gamma frequencies at baseline and after cannabis vapor exposure for both sham and NVHL rats. Figures were made using the brain
schematics available from Paxinos and Watson (2007).51
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expressed as means ± SEM or percent change from sham
baseline ± SEM.
Results
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Lesions and electrode placements were verified microscopically in NVHL and sham rats. All NVHL rats
showed bilateral lesions of the ventral hippocampus and
the electrodes were verified to be in the correct locations
(figure 1B). No animals were removed from the study nor
were the electrodes ever inactive. Representative traces of
theta and gamma oscillations obtained from the Cg are
shown in figure 1C.
To confirm that our study was appropriately powered,
we evaluated effect sizes for high gamma power and coherence in each brain region, where we saw the largest
variations in the data. We had large effect sizes (>1.1,
N = 8–10, power = 0.95) that were associated with a minimum 25% change in power/coherence.
Baseline gamma deficits in spectral power exist in
the Cg, HIP, and NAc of NVHL rats, when compared
to sham rats, and these deficits are selectively modified
by cannabis vapor exposure (figure 2). In the Cg, the
only baseline deficit apparent between NVHL and sham
rats was with high-gamma power (P = .021, figure 2A).
Balanced THC:CBD vapor exposure attenuated this
high-gamma baseline deficit in NVHL rats to levels above
baseline (figure 2A). THC-only vapor exposure reduced
Cg beta (P = .001) and low-gamma power (P = .019)
only in NVHL rats, as well as high-gamma power in
the sham rats (P = .016), effects that were no longer apparent after Balanced THC:CBD vapor exposure. Both
exposures enhanced delta power and reduced theta
power in the Cg of all rats (sham delta: F[2,14] = 6.7,
P = .009, theta: F[2,14] = 9.2, P = .003; NVHL delta:
F[2,14] = 3.5, P = 0.059, theta: F[2,14] = 7.5, P = .008;
figure 2A).
In the PrLC, baseline power was similar between
NVHL and sham rats across all frequency bands
(figure 2B). For NVHL rats, THC-only vapor exposure suppressed PrLC beta power while the Balanced
THC:CBD vapor exposure did not have this effect
(NVHL beta: F[2,14] = 8.9, P = .003). For all rats, both
exposures reduced theta power, and delta power to a
lesser degree (sham delta: F[2,14] = 5.6, P = .016, theta:
F[2,14 = 32.3, P < .001; NVHL delta: F[2,14] = 3.3,
P = .067, theta: F[2,14] = 20.6, P < .001), while THConly vapor exposure reduced low-gamma power (sham
low gamma: F[2,14] = 6.7, P = .009, high gamma:
F[2,14] = 4.4, P = .032; NVHL low gamma: F[2,14] = 4.0,
P = .042). Balanced THC:CBD vapor exposure did not
have any effect.
In the HIP of NVHL rats, baseline deficits in lowgamma (P = .044) and high-gamma (P = .047) power
were observed, compared to sham controls (figure 2C).
These significant differences between sham and NVHL

rats were no longer present after the Balanced THC:CBD
exposure and the THC-only vapor exposure did not produce any differences from baseline for either NVHL or
sham rats. Similarly, both exposures did not affect delta
power in NHVL or sham rats. Both exposures, however,
robustly suppressed theta power in all rats (sham theta:
F[2,14] = 32.3, P < .001; NVHL theta: F[2,14] = 20.6, P
< .001).
In the NAc, NVHL rats had baseline deficits in lowgamma power, compared to sham controls (P = .001,
figure 2D). THC-only vapor exposure increased NAc
delta power for all rats while the Balanced THC:CBD exposure enhanced delta power for sham rats only (sham
delta: F[2,14] = 4.7, P = .027; NVHL delta: F[2,14] = 6.6,
P = .010). Notably, THC-only vapor exposure reduced
spectral power across all other frequencies in both NVHL
and sham rats, while the Balanced THC:CBD exposure
did not produce any significant change from baseline for
NVHL rats across all frequencies, or for sham rats in the
gamma frequency band; this exposure; however, reduced
theta power in sham rats (sham theta: F[2,14] = 13.2,
P = .001; low gamma: F[2,14] = 4.8, P = .026; high gamma:
F[2,14] = 9.9, P = .002; NVHL theta: F[2,14] = 7.8,
P = 0.005; beta: F[2,14] = 10.3, P = .002; low gamma:
F[2,14] = 8.0, P = .005; high gamma: F[2,14] = 15.6,
P = .001).
Assessing oscillatory coherence between target
brain regions revealed that baseline differences exist
between NVHL and sham rats and are modifiable by
cannabinoid exposure (figure 3). Compared to sham
rats, NVHL rats exhibited reduced high-gamma
power between the HIP-Cg (P = .041, figure 3A).
THC-only exposure reduced HIP-NAc high-gamma
coherence in NVHL rats (P = .018, figure 3B). Both
cannabis vapor exposures enhanced Cg-PrLC delta coherence in NVHL rats to levels above sham baseline
coherence (THC: P = .005; THC:CBD: P = 0.039;
figure 3C). Cannabis vapor exposure did not alter HIPPrLC (figure 3D), NAc-Cg (figure 3E), or NAc-PrLC
(figure 3F) coherence.
Cross-correlation analysis revealed baseline deficits in
NVHL rats of phase coupling between HIP theta and
gamma in the Cg, PrLC, or NAc that are sensitive to the
effects of cannabis vapor exposure (figure 4). Comparing
theta-gamma coupling strength between NVHL and
sham rats revealed similar baseline values for all regionpair comparisons; however, compared to sham rats,
NVHL rats exhibited a 20 ms delay in coupling of HIP
theta to Cg, PrLC, and NAc high-gamma. This delay was
not apparent in the PrLC and NAc region-pairs after
both vapor exposures (figure 4B,C) but was observed
in the Cg (figure 4A). For all rats, the THC-only vapor
exposure also enhanced the HIP theta-gamma coupling strength between all regions. This effect was also
observed to a lesser extent after the Balanced THC:CBD
vapor exposure.
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Fig. 2. NVHL rats exhibit reduced baseline spectral power compared to sham rats, and cannabis vapor differentially modulates this
dysfunction. A) Spectral power tracing (left) and quantification (right) in the Cg showing baseline deficits in high-gamma power for
NVHL rats (N = 5 rats, 10 recordings per region) compared to sham rats (N = 5 rats, 10 recordings per region); THC-only vapor reduced
Cg beta and low-gamma power only in NVHL rats, an effect that was no longer apparent after Balanced THC:CBD vapor exposure;
Balanced THC:CBD vapor exposure also attenuated the high-gamma baseline deficit in NVHL rats; both exposures enhanced delta,
and reduced theta, power in the Cg of all rats; B) In NVHL rats, THC-only vapor exposure suppressed PrLC beta power while the
THC:CBD-vapor exposure did not; for all rats, both exposures reduced theta power, and delta power to a lesser degree, while THConly vapor exposure reduced both low- and high-gamma power; Balanced THC:CBD vapor exposure did not have any effect; C) In the
HIP, NVHL rats showed baseline deficits in low- and high-gamma power, compared to sham rats whereas Balanced THC:CBD vapor
exposure appeared to marginally improve baseline deficits; both exposures did not affect delta power and robustly suppressed theta
power in NHVL and sham rats. D) In the NAc, NVHL rats showed baseline deficits in low-gamma power, compared to sham controls;
THC-only vapor exposure reduced spectral power across all other frequencies in both NVHL and sham rats; THC:CBD exposure did
not change from baseline measures any frequencies for NVHL rats, and selectively changed the gamma frequency band for sham rats. *P
< .05; **P < .01 compared to sham control baseline; ##P < .05 compared to NVHL rat baseline; φP < .05 compared THC-only treated
rats to THC:CBD treated rats.
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Discussion
This study assessed differences in baseline oscillatory activity between the NVHL rat model of schizophrenia and
sham animals, as well as changes in oscillatory activity
after exposure to THC-containing cannabis vapor with
or without CBD. Our results (summarized in figure 5)
demonstrate that NVHL rats have reduced baseline
gamma power and coherence compared to sham-surgery
controls, mirroring observations from clinical studies in
patients with schizophrenia. Interestingly, baseline measures of delta, theta, and beta power from NVHL rats were
not different from sham rats. This contradicts existing
preclinical evidence of reduced theta (5–15 Hz) and beta
(20–30 Hz) coherence in the HIP of NVHL rats, along
with intact PFC coherence (which was corroborated in
this study), as well as reduced theta (4–12 Hz) power
in the PrLC and HIP of DISC1 knock-out mice or the
enhanced theta and beta power in the parietal cortex of
selectively bred Wistar rats that was reported above.30,32,52
Moreover, whole-brain EEG recordings of cortical oscillatory activity demonstrate that delta, theta, alpha, and

beta power is enhanced in patients with schizophrenia
compared to healthy controls, along with enhanced
delta and alpha coherence between various brain regions.53–55 Given that alterations observed in NVHL
rats are not due directly to the lesion but are instead a
result of the neurodevelopmental insult during the neonatal period,34–36 it could be that the contradictory results
are caused by different neurodevelopmental trajectories
influenced by varying genetic and environmental factors.
The discordance between the present study and existing
preclinical studies may also be due to the use of different
rodent strains to produce these models (Long Evans rats,
C57BL/6J mice, and Wistar rats, respectively, in the papers cited above), while the variance between clinical
and preclinical studies may be explained by the inherent
differences in oscillatory activity that exist between
rodents and humans.56 Head-to-head studies are required
to completely characterize the strain- and species-related
differences.
For all rats in this study, the THC-only vapor exposure suppressed spectral power in all brain regions and
across all frequencies except delta, while the Balanced
Page 7 of 14
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Fig. 3. NVHL rats exhibit reduced baseline coherence within and between cortical and limbic regions, with variable impacts of cannabis
vapor. A) Both vapor exposures enhanced HIP-Cg high-gamma coherence in the NVHL rats (N = 5 rats, 10 recordings per region) to
levels that were no longer different from sham (N = 5 rats, 10 recordings per region) baseline coherence; B) THC-only vapor exposure
reduced HIP-NAc high-gamma coherence in NVHL rats; C) Both types of cannabis-vapor exposures enhanced Cg-PrLC delta coherence
in NVHL rats to levels above baseline coherence in sham rats; Cannabis vapor exposure did not alter D) HIP-PrLC, E) NAc-Cg, or F)
NAc-PrLC coherence. *P < .05; **P < .01 compared to sham control baseline.

B. W. Jenkins et al

THC:CBD vapor exposure reduced theta power in all
brain regions (except the NAc for NVHL rats), delta
power in the PrLC, and beta power in the NAc (selectively in sham rats). THC modulates brain signals and behavior in otherwise healthy subjects, and in patients with
schizophrenia. When administered intravenously (IV) to
healthy subjects, THC (2.5 mg, 5 mg) produces transient
states of psychosis57–59 that dose-dependently (at 0.03 mg/
kg, but not 0.015 mg/kg, IV) correlate with reduced coherence of gamma frequency oscillations (30–100 Hz).60
When THC (1.25 mg; IV) is administered to patients with
schizophrenia, it differentially alters cortical oscillations,
reducing slow-wave spectral power (below 27 Hz) and
enhancing gamma frequency power (above 27 Hz),61
while also transiently exacerbating the positive, negative, and cognitive symptoms of schizophrenia including
learning, memory, and perceptual deficits (2.5 mg, 5 mg;
Page 8 of 14

IV THC).9,62 This is contrasted by evidence that synthetic THC (dronabinol; 5 mg to 20 mg/day) reduces
psychotic symptoms in patients.63–65 To further characterize the changes in neural circuit activity correlated
with cannabis use and the symptoms of schizophrenia,
we previously assessed DMN functional connectivity in
patients with co-occurring schizophrenia and cannabis
use disorder, compared to healthy controls, using MRI
scans taken before and after subjects smoked cannabis
(3.6% THC) or ingested THC (15 mg).66 Before cannabis
exposure, patients exhibited DMN hyperconnectivity
compared to controls, and this hyperconnectivity was
correlated with positive symptom severity; patients also
exhibited reduced anticorrelation between the DMN and
ECN. Cannabis exposure reduced hyperconnectivity and
increased anticorrelation. Working memory performance
was also assessed and found to be positively correlated
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Fig. 4. NVHL rats exhibit baseline deficits in phase coupling between HIP theta and Cg, PrLC, or NAc gamma, and cannabis vapor
exposure selectively alters this delay. A–C) NVHL rats (N = 5 rats, 10 recordings per region) exhibited a 20 ms delay in coupling of HIP
theta to high-gamma in the Cg, PrLC, and NAc; both vapor exposures reversed this delay in the B) PrLC and C) NAc, but not in the A)
Cg; For all rats, the THC-only vapor exposure also enhanced the HIP theta–gamma coupling strength in all regions, an effect that was
also observed to a lesser extent after Balanced THC:CBD vapor exposure; NVHL rats exhibited baseline theta–gamma coupling strength
similar to sham rats (N = 5 rats, 10 recordings per region), for all pairwise comparisons. *P < .05; **P < .01 compared to sham control
baseline. θ = theta frequency band; γ = gamma frequency band.

Cannabis Constituents And Schizophrenia-like Oscillations

with the magnitude of anticorrelation in controls and
patients that were administered cannabis.68
In NVHL rats, gamma power remained largely unchanged by the Balanced THC:CBD vapor exposure,
although this exposure enhanced Cg and NAc gamma
power in NVHL rats toward sham baseline levels, and
enhanced Cg delta power for all rats. Interestingly, the
enhancing or neutral effects of the Balanced THC:CBD
vapor exposure was most pronounced in NVHL rats,
compared to sham rats, which did not display the baseline

deficits observed in the NVHL rats. After both exposures,
Cg-PrLC delta coherence was enhanced for NVHL rats,
whereas the THC-only exposure exacerbated HIP-NAc
coherence. The baseline 20 ms-delay deficit in phase
coupling observed in NVHL rats was also no longer apparent after both exposures, for all regions but the Cg.
Taken together, while the exposure to THC-containing
cannabis vapor without CBD broadly suppressed oscillatory power similarly for all rats, NVHL rats may be differentially susceptible to shifts in oscillatory power and
Page 9 of 14
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Fig. 5. Graphical summary of power, coherence and phase coupling changes associated with NVHL lesions and cannabis vapor
exposure. Cannabis vapor exposure produced constituent- and region-dependent disruptions in neural circuit oscillatory activity, often
reducing theta, beta, and gamma power while enhancing delta power. Cannabis vapor exposure also enhanced coherence in cortical
regions while reducing coherence and phase coupling between limbic regions. Cannabis vapor exposure further exacerbated baseline
NAc, Cg, HIP gamma power deficits apparent in NVHL rats (N = 5 rats, 10 recordings per region), compared to sham controls (N = 5
rats, 10 recordings per region). PrLC = prelimbic cortex; NAc = nucleus accumbens; Cg = cingulate cortex; HIP = hippocampus.
Δ = delta frequency band; θ = theta frequency band; β = beta frequency band; γ = gamma frequency band. Green = increase;
red = decrease. Icons represent comparisons to sham baseline values and thus “N/A” is used for baseline sham findings. Figure was made
using the brain schematics available from Swanson (2018).67
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brain regions (recently reviewed by Gunasekera et al.75).
CB1R activation in the PrLC of rats via administration
of CP-55,940 (0.7 mg/kg, IP) and agonist WIN55,212-2
(1.2 mg/kg, IP) alters local excitatory and inhibitory
signaling76 while administration of THC (0.3–10 mg/kg,
IP) and CBD (15, 30, or 60 nmol, intracranial infusion; 1
and 3 mg/kg, IP) attenuates schizophrenia-like behaviors,
including fear memory and anxiety-related behaviors.77,78
Although preclinical studies of cannabinoid activity in the
Cg remains focused on analgesia and pain mechanisms,
evidence exists showing CB1R activation in the Cg via
local injection of agonist arachidonyl-2-chloroethylamide
(ACEA) impairs decision-making in rats, reducing motivation for seeking large rewards, measured using a
T-maze decision-making task.79 In clinical studies, MRI
assessments of Cg volume in patients with schizophrenia
using or abstaining from cannabis reveals patients using
cannabis have reduced grey-matter volume, compared
to patients not using cannabis and to healthy controls.80
Furthermore, postmortem analysis of brain samples
from patients with schizophrenia reveal increased CB1R
binding in the anterior Cg,81 although this is contested.82
Numerous preclinical and clinical investigations implicate
the HIP in the effects of cannabis and of schizophrenia,
with reproduced evidence that CP-55,940 administration
(0.3 mg/kg, IP; 0.1 mg/kg, IV) in rats reduces HIP theta
(4–10 Hz) and gamma (30–90 Hz) oscillatory power.38,83
Furthermore, NVHL rats demonstrate shifts in baseline
oscillatory coherence in favor of slow-wave frequencies,
with reports of enhanced HIP theta (10 Hz) and reduced
gamma (50 Hz) phase-locking in the HIP,33 mirroring
clinical observations cited above61; however, reduced HIP
theta (5–15 Hz) power in NVHL rats is also reported.32
Finally, preclinical evidence exists demonstrating rats
used to model schizophrenia have aberrant, high frequency (>100 Hz) oscillations in this region, and this
is mediated by the endocannabinoid system (ECS).84,85
Additionally, ECS modulation via CB1R antagonism
with rimonabant (0.3 mg/kg, IV) reduces stereotypical
enhancements of NAc gamma power (30–70 Hz) in a rat
model of amphetamine-induced psychosis.86
Additionally, the differential sensitivity of patients
with schizophrenia to cannabinoid exposure may be due
in part to the involvement of the endocannabinoid system
(ECS) in the etiology of the disorder. Patients with schizophrenia have altered ECS functioning, evidenced by elevated levels of the endocannabinoid anandamide and
postmortem CB1R expression in patients.87,88 Exposure to
exogenous cannabinoids may shift the homeostatic norm
in patients such that it acutely restores system function in
some regions to levels associated with typical functioning,
while concurrently exacerbating dysfunctions in other
regions. Importantly, our results posit a question of
whether advising patients to consume cannabis with balanced THC:CBD levels could be a viable harm reduction
strategy.
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coherence induced by THC-containing cannabis vapor
exposure when CBD is present in the plant matter.
These data support past observations that CBD
opposes some of the effects of THC. Intracranial infusion
of THC (100 ng) directly into the ventral HIP (vHIP) of
anesthetized male Sprague Dawley rats enhances downstream VTA neuronal firing and bursting rates, as well as
beta and gamma power. Rats that were infused with CBD
(100 ng) or co-infused with THC + CBD (100 ng each)
demonstrated no difference in oscillatory power when
compared to vehicle-treated controls.24 Phosphorylated
ERK was up-regulated after THC administration and
down-regulated after THC + CBD administration,
whereas CBD alone did not change phosphorylated
ERK expression. That said, more research is needed to
fully characterize the causal mechanisms underlying this
oppositional effect and the relative contribution of each
cannabinoid (as well as other potential components (e.g.,
terpenes) of the cannabis plant that could have differed
between our two cannabis types). Some variance may also
arise from the use of different administration routes,69 as
we chose a protocol with greater translational relevance
(i.e., vapor inhalation rather than IV injection),69 or the
doses administered, as previous research using the PCP
rat model of schizophrenia demonstrates through singleunit recordings in the VTA, before and after two doses of
THC (0.1 mg/kg and 1 mg/kg, IP), that baseline deficits
in the number of active VTA neurons in PCP rats are
reversed only by exposure to the low dose. Both the low
and high dose decreased the number of active neurons in
control rats.70 PCP rats administered THC (1 mg/kg, IP)
also demonstrate dysfunctional PrLC activity, evidenced
by an absence of the THC-induced disinhibition of neuronal firing observed in controls rats.71
Our results corroborate existing clinical observations
of oral CBD (600 mg) normalizing mediotemporal,
mediotemporal-striatal, and prefrontal cortical activity,
measured using functional MRI in patients with schizophrenia; importantly, this normalization of brain activity
corresponded with improvements in self-reported symptom
severity,72 extending the growing body of literature on the
antipsychotic potential of CBD.73 Preclinical evidence
also demonstrates that antipsychotic administration
normalizes aberrant PFC delta (1–4 Hz) and theta (4–12
Hz) power and coherence of the methylazoxymethanol rat
model of schizophrenia.74 Considering this, we plan to investigate the electrophysiological changes produced after
exposure to a “CBD-only” cannabis flower vapor (i.e., exposure to cannabis flower vapor containing a moderate to
high amount of CBD and near-zero amounts of THC) in
future studies. We expect that the CBD-only exposure will
not reduce oscillatory power and coherence in NVHL and
sham rats, while it may in some instances enhance activity;
particularly for NVHL rats.
Relevant to this study, the oppositional effects of
CBD on THC-induced changes are evident in our target
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patients with schizophrenia that relates to symptomatic
sensory processing deficits.94 Finally, impaired theta–
gamma phase coupling is apparent in patients with schizophrenia, compared to healthy controls, and is associated
with working memory impairments.95 Interestingly,
theta–gamma phase coupling was improved in patients
with schizophrenia that were using cannabis in addition
to nicotine, compared to patients only using nicotine.96
To conclude, the results of this study reveal that cannabis has a varying impact on oscillatory activity and
the administration route, dose, and relative composition
of natural or synthetic cannabinoids may be partly responsible for the varying cannabis-related outcomes reported in patients with schizophrenia.
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